FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma
The FDA has granted a priority review designation to a biologics license application for belantamab mafodotin as a treatment for patients with relapsed/refractory multiple myeloma who received prior therapy with an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
Source: OncLive